|
Relationship between tumor parameters in Ga-68 PSMA PET/CT and pathological grade grouping in patients with prostate cancer
|
F. Demir   , S. Karaçavuş , H. Gençer , A. Özdal , Z. Erdoğan , İ. Çiftçi , F. Çevik Kaya , N. Özhan , H. İşçi , M. Kaya |
| Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey , drfadimedemir@hotmail.com |
|
|
Abstract: (563 Views) |
Background: The study aims to explore the relationship between tumor parameters acquired from Ga-68 PSMA PET/CT and GG system in patients who had prostate cancer. Materials and Methods: One hundred and fourteen patients diagnosed with prostate cancer and who underwent Ga-68 PSMA PET/CT imaging for staging purposes were enrolled. The imaging was performed using a Siemens Biograph Horizon-3R 16 slice PET/CT device, and the tumor parameters (SUVmax, SUVmean, and Tumor volume) were calculated by an experienced nuclear medicine physician. Results: There was a correlation between GG with SUVmax (p:0.010; r:0.241) and SUVmean (p:0.06; r:0.258). In redicting high-risk patients, ROC analysis was conducted for SUVmax and SUVmean, resulting in significant cut-off values for both parameters. A cut-off value of 9.8 for SUVmax resulted in a sensitivity of 69% and a specificity of 58%. 5.8 cut-off value for SUVmean resulted in 68% sensitivity and 58% specificity. Tumor volume was found to be a significant predictor for distant metastasis. When a cut-off value of 11.53 cm3 was used for tumor volume, sensitivity was found to be 62% and specificity 56%. Conclusion: According to the results, correlation between GG with SUVmax and SUVmax was significant. Additionally, SUVmax and SUVmean were significant predictors of high-risk prostate cancer, while TV was a significant predictor of distant metastases. In summary, Ga-68-PSMA PET CT are deemed a beneficial imaging modality for both prognosis assessment and staging in clinical. |
|
| Keywords: Ga-68 PSMA PET/CT, prostate cancer, pathological grade grouping. |
|
|
Full-Text [PDF 667 kb]
(128 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. (2021) Epidemiology and prevention of prostate cancer. Eur Urol Oncol, 4(6): 877-892. [ DOI:10.1016/j.euo.2021.09.006] 2. Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele (2022) Prostate Cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules, 27(17): 5730. [ DOI:10.3390/molecules27175730] 3. Sehn JK (2018) Prostate cancer pathology: Recent updates and controversies. Mo Med, 115(2): 151-155. 4. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016). The 2014 International Society of Urological Pathology (ISUP) Consensus conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol, 40(2): 244-52. [ DOI:10.1097/PAS.0000000000000530] 5. Sehn JK (2018) Prostate Cancer Pathology: Recent Updates and Controversies. Mo Med, 115(2): 151-155. 6. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO Classification of tumours of the urinary system and male genital organs-Part B: Prostate and bladder tumours. Eur Urol, 70(1): 106-119. [ DOI:10.1016/j.eururo.2016.02.028] 7. Lorenc T, Klimczyk K, Michalczewska I, Słomka M, Kubiak-Tomaszewska G, Olejarz W (2020) Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy. Int J Mol Sci, 21(6): 2118. [ DOI:10.3390/ijms21062118] 8. Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. (2017) PSMA Ligands for PET ımaging of prostate cancer. J Nucl Med, 58(10): 1545-1552. [ DOI:10.2967/jnumed.117.191031] 9. Schlemmer HP, Krause BJ, Schütz V, Bonekamp D, Schwarzenböck SM, Hohenfellner M (2021) Imaging of prostate cancer. Dtsch Arztebl Int, 118(42): 713-719. [ DOI:10.3238/arztebl.m2021.0309] 10. Ghafoor S, Burger IA, Vargas AH (2019) Multimodality ımaging of prostate cancer. J Nucl Med, 60(10): 1350-1358. [ DOI:10.2967/jnumed.119.228320] 11. Demirci E, Kabasakal L, Şahin OE, Akgün E, Gültekin MH, Doğanca T, et al. (2019) Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun, 40(1): 86-91. [ DOI:10.1097/MNM.0000000000000942] 12. Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. (2022) The PRIMARY Score: Using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis. J Nucl Med, 63(11): 1644-1650. 13. Kesler M, Cohen D, Levine C, Sarid D, Keizman D, Yossepowitch O, Even-Sapir E (2023) Staging prostate cancer with 68Ga-PSMA-11 PET/CT in the elderly: Is preimaging biopsy ımperative? J Nucl Med, 64(7): 1030-1035. [ DOI:10.2967/jnumed.122.265371] 14. Wong LM, Koschel S, Whish-Wilson T, Farag M, Bolton D, Zargar H, et al. (2023) Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance. World J Urol, 41(2): 463-469. [ DOI:10.1007/s00345-022-04243-5] 15. Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, et al. (2018) The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol, 70(5): 462-478. [ DOI:10.23736/S0393-2249.18.03081-3] 16. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and meta-analysis. Eur Urol, 77(4): 403-417. [ DOI:10.1016/j.eururo.2019.01.049] 17. Barakzai MA (2019) Prostatic Adenocarcinoma: A Grading from Gleason to the new grade-group system: A historical and critical review. Asian Pac J Cancer Prev, 20(3): 661-666. [ DOI:10.31557/APJCP.2019.20.3.661] 18. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, et al. (2019) Prostate cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17(5): 479-505. [ DOI:10.6004/jnccn.2019.0100] 19. Liu FY, Sheng TW, Tseng JR, Yu KJ, Tsui KH, Pang ST, Wang LJ, Lin G (2022) Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET-CT vs PET-MRI. Br J Radiol, 95(1131): 20210728. [ DOI:10.1259/bjr.20210728] 20. Combes AD, Palma CA, Calopedos R, Wen L, Woo H, Fulham M, Leslie S (2022) PSMA PET-CT in the diagnosis and staging of prostate cancer. Diagnostics (Basel), 12(11): 2594. [ DOI:10.3390/diagnostics12112594] 21. Awenat S, Piccardo A, Carvoeiras P, Signore G, Giovanella L, Prior JO, Treglia G (2021) Diagnostic role of 18F-PSMA-1007 PET/CT in prostate cancer staging: A systematic review. Diagnostics (Basel), 11(3): 552. [ DOI:10.3390/diagnostics11030552] 22. Kim HJ, Lee JS, Kim WC (2020) Clinical outcome of stereotactic body radiotherapy for localized prostate cancer: long -term results. Int J Radiat Res, 18(3): 383-388. 23. Chen M, Qiu X, Zhang Q, Zhang C, Zhou YH, Zhao X, Fu Y, Wang F, Guo H (2022) PSMA uptake on [68Ga]-PSMA-11-PET/CT positively correlates with prostate cancer aggressiveness. Q J Nucl Med Mol Imaging, 66(1): 67-73. [ DOI:10.23736/S1824-4785.19.03172-8] 24. Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H (2021) Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients. Ann Nucl Med, 35(5): 540-548. [ DOI:10.1007/s12149-021-01594-8] 25. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. (2017) 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging, 44(6): 941-949. [ DOI:10.1007/s00259-017-3631-6] 26. Erdoğan M, Özkan EE, Öztürk SA, Yıldız M, Şengül SS (2020) The role of Ga-68 PSMA PET/CT scan on differentiating of oligometastatic and high risk prostate cancer. Mol Imaging Radionucl Ther, 29(3): 98-104. [ DOI:10.4274/mirt.galenos.2020.89421] 27. Pepe P, Pepe L, Tamburo M, Marletta G, Savoca F, Pennisi M, Fraggetta F (2023) 68Ga-PSMA PET/CT and prostate cancer diagnosis: Which SUVmax value? In Vivo, 37(3): 1318-1322. [ DOI:10.21873/invivo.13211] 28. Dong S, Li Y, Chen J, Li Y, Yang P, Li J (2022) 18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer. Front Oncol, 12: 1025930. [ DOI:10.3389/fonc.2022.1025930] 29. Xie Y, Li C, Zhang L, Zang S, Yu F, Wang S, Wang F (2022) 68Ga-PSMA-I&T PET/CT for assessment of tumor burden in primary lesions of treatmentnaïve prostate cancer. Nan Fang Yi Ke Da Xue Xue Bao, 42(8): 1143-1148.
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Demir F, Karaçavuş S, Gençer H, Özdal A, Erdoğan Z, Çiftçi İ, et al . Relationship between tumor parameters in Ga-68 PSMA PET/CT and pathological grade grouping in patients with prostate cancer. Int J Radiat Res 2025; 23 (2) :277-281 URL: http://ijrr.com/article-1-6224-en.html
|
